Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : Tseng Lab on the move? -- Ignore unavailable to you. Want to Upgrade?

To: Scott Halpert who wrote (246)	11/2/1998 10:50:00 PM
From: bob	Read Replies (1) \| Respond to of 251

Scott, I was one of the many today that were a bit surprised at the selling of TSNG, and after reading Mr. Berger's post I became even more confused. There never was an IPO planned and as far as I can tell nothing has changed with the exception that I for one thought that a secondary offering was planned. A subsequent call to CPI today confirmed that none is planned for the immediate future. How Mr. Berger can affix a price to this merger is beyond me. Book value is certainly not what people value here, it is the potential for the future with CPI's medications, including Prevatac which is in late Stage III clinical trials for APC and earlier human clinical trials, both Stage II and III, for various forms of cancer and its chemoprevention. Of course no value is given to the fact that FGN-1 is on the Fast-Track for FDA approval either. If this stock trades at strictly book value we are all in trouble! Bob